[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Medical News & Perspectives
April 14, 1999

High-Tech Angina Relief Explored in Treatment Trials

Author Affiliations

Not Available

Not Available

JAMA. 1999;281(14):1258-1260. doi:10.1001/jama.281.14.1258-JMN0414-2-1

New Orleans—People with intractable angina received discouraging and encouraging news from researchers presenting data at the American College of Cardiology's annual meeting held here in early March.

In the headline-grabbing field of gene transfer, results of the first large, double-blind, placebo-controlled trial of therapeutic angiogenesis in patients with severe angina showed, essentially, that the therapy worked only as well as the placebo. While researchers presenting the data warned that their results are preliminary and insisted that it's too early to dismiss gene therapy as a treatment for angina, Genentech Inc, manufacturer of the tested recombinant human vascular endothelial growth factor (rhVEGF 165), called the results "disappointing."

First Page Preview View Large
First page PDF preview
First page PDF preview